MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze To judge several intravenous doses of sifalimumab, in adult sufferers with dermatomyositis or polymyositis (NCT00533091). Principal trial objectives were To judge the security and tolerability of sifalimumab in dermatomyositis or polymyositis clients, though among the exploratory... https://e744988765.blogdemls.com/30732422/the-2-minute-rule-for-qst4